{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:12Z","timestamp":1786979892488,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"crossref","award":["NUHSRO\/2021\/097\/Startup\/13"],"award-info":[{"award-number":["NUHSRO\/2021\/097\/Startup\/13"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00259-024-06930-4","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T05:02:14Z","timestamp":1728968534000},"page":"683-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["[68Ga]Ga-LNC1007 versus 2-[18F]FDG in the evaluation of patients with metastatic differentiated thyroid cancer: a head-to-head comparative study"],"prefix":"10.1007","volume":"52","author":[{"given":"Yun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-1813","authenticated-orcid":false,"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"6930_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271\u201389. https:\/\/doi.org\/10.3322\/caac.21349.","journal-title":"CA Cancer J Clin"},{"key":"6930_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"key":"6930_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/cancers12030625.2","volume":"3","author":"H Kim","year":"2020","unstructured":"Kim H, Park SY, Choe JH, Kim JS, Hahn SY, Kim SW, et al. Preoperative serum thyroglobulin and its correlation with the burden and extent of differentiated thyroid cancer. Cancers (Basel). 2020;3:625. https:\/\/doi.org\/10.3390\/cancers12030625.2.","journal-title":"Cancers (Basel)"},{"key":"6930_CR4","doi-asserted-by":"publisher","first-page":"100939","DOI":"10.1016\/j.drup.2023.100939","volume":"68","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang J, Hu X, Pan Z, Xu T, Xu J, et al. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resist Updat. 2023;68:100939. https:\/\/doi.org\/10.1016\/j.drup.2023.100939.","journal-title":"Drug Resist Updat"},{"key":"6930_CR5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1089\/thy.2011.0535","volume":"22","author":"IJ Nixon","year":"2012","unstructured":"Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR, Shah JP, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22:884\u20139. https:\/\/doi.org\/10.1089\/thy.2011.0535.","journal-title":"Thyroid"},{"key":"6930_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1089\/thy.2023.0264","volume":"33","author":"JI Bang","year":"2023","unstructured":"Bang JI, Park S, Kim K, Seo Y, Chong A, Hong CM, et al. The diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin\/thyroglobulin antibody levels and negative iodine scintigraphy: a systematic review and meta-analysis. Thyroid. 2023;33:1224\u201336. https:\/\/doi.org\/10.1089\/thy.2023.0264.","journal-title":"Thyroid"},{"key":"6930_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/mnm.0000000000001758","volume":"44","author":"M Haidar","year":"2023","unstructured":"Haidar M, Kassas M, Chehade F, Chahinian R, Abi-Ghosn J, Haddad MM. The role of 18 F-FDG-PET\/CT in the management of differentiated thyroid cancer. Nucl Med Commun. 2023;44:1046\u201352. https:\/\/doi.org\/10.1097\/mnm.0000000000001758.","journal-title":"Nucl Med Commun"},{"key":"6930_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s00259-007-0692-y","volume":"35","author":"ZB Li","year":"2008","unstructured":"Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging. 2008;35:1100\u20138. https:\/\/doi.org\/10.1007\/s00259-007-0692-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6930_CR9","first-page":"1172","volume":"47","author":"W Cai","year":"2006","unstructured":"Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4\u201318F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med. 2006;47:1172\u201380.","journal-title":"J Nucl Med"},{"key":"6930_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1089\/thy.2019.0450","volume":"30","author":"AS Parihar","year":"2020","unstructured":"Parihar AS, Mittal BR, Kumar R, Shukla J, Bhattacharya A. (68)Ga-DOTA-RGD(2) Positron emission tomography\/computed tomography in radioiodine refractory thyroid cancer: prospective comparison of diagnostic accuracy with (18)F-FDG positron emission tomography\/computed tomography and evaluation toward potential theranostics. Thyroid. 2020;30:557\u201367. https:\/\/doi.org\/10.1089\/thy.2019.0450.","journal-title":"Thyroid"},{"key":"6930_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s12149-022-01742-8","volume":"36","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zheng S, Zhang J, Yao S, Miao W. (68)Ga-DOTA-FAPI-04 PET\/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. Ann Nucl Med. 2022;36:610\u201322. https:\/\/doi.org\/10.1007\/s12149-022-01742-8.","journal-title":"Ann Nucl Med"},{"key":"6930_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1148\/radiol.212430","volume":"304","author":"H Fu","year":"2022","unstructured":"Fu H, Wu J, Huang J, Sun L, Wu H, Guo W, et al. (68)Ga Fibroblast activation protein inhibitor PET\/CT in the detection of metastatic thyroid cancer: comparison with (18)F-FDG PET\/CT. Radiology. 2022;304:397\u2013405. https:\/\/doi.org\/10.1148\/radiol.212430.","journal-title":"Radiology"},{"key":"6930_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06587-5","author":"N Liu","year":"2024","unstructured":"Liu N, Wan Q, Wu X, Zhao T, Jakobsson V, Yuan H, et al. A comparison of [(18)F]AlF- and (68)Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET\/CT imaging. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-023-06587-5. Epub ahead of print.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6930_CR14","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.7150\/thno.79144","volume":"12","author":"J Zang","year":"2022","unstructured":"Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, et al. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [(68)Ga]Ga-FAPI-RGD. Theranostics. 2022;12:7180\u201390. https:\/\/doi.org\/10.7150\/thno.79144.","journal-title":"Theranostics"},{"key":"6930_CR15","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.122.265383","volume":"64","author":"L Zhao","year":"2023","unstructured":"Zhao L, Wen X, Xu W, Pang Y, Sun L, Wu X, et al. Clinical evaluation of (68)Ga-FAPI-RGD for imaging of fibroblast activation protein and integrin \u03b1(v)\u03b2(3) in various cancer types. J Nucl Med. 2023;64:1210\u20137. https:\/\/doi.org\/10.2967\/jnumed.122.265383.","journal-title":"J Nucl Med"},{"key":"6930_CR16","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.7150\/thno.86007","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Jakobsson V, Wang J, Zhao T, Peng X, Li B, et al. Dual targeting PET tracer [(68)Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study. Theranostics. 2023;13:2979\u201392. https:\/\/doi.org\/10.7150\/thno.86007.","journal-title":"Theranostics"},{"key":"6930_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00259-023-06436-5","volume":"51","author":"R Lin","year":"2024","unstructured":"Lin R, Wang C, Chen S, Lin T, Cai H, Chen S, et al. [(68)Ga]Ga-LNC1007 PET\/CT in the evaluation of renal cell carcinoma: comparison with 2-[(18)F]FDG\/[(68)Ga]Ga-PSMA PET\/CT. Eur J Nucl Med Mol Imaging. 2024;51:535\u201347. https:\/\/doi.org\/10.1007\/s00259-023-06436-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6930_CR18","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1097\/rlu.0000000000004523","volume":"48","author":"S Zheng","year":"2023","unstructured":"Zheng S, Lin J, Zhu Y, Chen Y, Zhang J, Chen X, et al. 68Ga-FAPI Versus 18F-FDG PET\/CT in evaluating newly diagnosed breast cancer patients: a head-to-head comparative study. Clin Nucl Med. 2023;48:e104\u20139. https:\/\/doi.org\/10.1097\/rlu.0000000000004523.","journal-title":"Clin Nucl Med"},{"key":"6930_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11307-018-1216-9","volume":"21","author":"Y Dong","year":"2019","unstructured":"Dong Y, Wei Y, Chen G, Huang Y, Song P, Liu S, et al. Relationship between clinicopathological characteristics and PET\/CT uptake in esophageal squamous cell carcinoma: [(18)F]Alfatide versus [(18)F]FDG. Mol Imaging Biol. 2019;21:175\u201382. https:\/\/doi.org\/10.1007\/s11307-018-1216-9.","journal-title":"Mol Imaging Biol"},{"key":"6930_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1148\/radiol.2016150813","volume":"281","author":"X Jin","year":"2016","unstructured":"Jin X, Liang N, Wang M, Meng Y, Jia B, Shi X, et al. Integrin imaging with (99m)Tc-3PRGD2 SPECT\/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer. Radiology. 2016;281:958\u201366. https:\/\/doi.org\/10.1148\/radiol.2016150813.","journal-title":"Radiology"},{"key":"6930_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/rlu.0000000000003998","volume":"47","author":"Q Shang","year":"2022","unstructured":"Shang Q, Zhao L, Pang Y, Meng T, Chen H. Differentiation of reactive lymph nodes and tumor metastatic lymph nodes with 68Ga-FAPI PET\/CT in a patient with squamous cell lung cancer. Clin Nucl Med. 2022;47:458\u201361. https:\/\/doi.org\/10.1097\/rlu.0000000000003998.","journal-title":"Clin Nucl Med"},{"key":"6930_CR22","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1007\/s00259-022-05818-5","volume":"49","author":"X Zhou","year":"2022","unstructured":"Zhou X, Wang S, Xu X, Meng X, Zhang H, Zhang A, et al. Higher accuracy of [(68) Ga]Ga-DOTA-FAPI-04 PET\/CT comparing with 2-[(18)F]FDG PET\/CT in clinical staging of NSCLC. Eur J Nucl Med Mol Imaging. 2022;49:2983\u201393. https:\/\/doi.org\/10.1007\/s00259-022-05818-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6930_CR23","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s12149-021-01673-w","volume":"35","author":"S Zheng","year":"2021","unstructured":"Zheng S, Lin R, Chen S, Zheng J, Lin Z, Zhang Y, et al. Characterization of the benign lesions with increased (68)Ga-FAPI-04 uptake in PET\/CT. Ann Nucl Med. 2021;35:1312\u201320. https:\/\/doi.org\/10.1007\/s12149-021-01673-w.","journal-title":"Ann Nucl Med"},{"key":"6930_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/rlu.0000000000003623","volume":"46","author":"R Lin","year":"2021","unstructured":"Lin R, Lin Z, Zhang J, Yao S, Miao W. Increased 68Ga-FAPI-04 uptake in schmorl node in a patient with gastric cancer. Clin Nucl Med. 2021;46:700\u20132. https:\/\/doi.org\/10.1097\/rlu.0000000000003623.","journal-title":"Clin Nucl Med"},{"key":"6930_CR25","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/rlu.0000000000003810","volume":"46","author":"M Assadi","year":"2021","unstructured":"Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and therapeutic potential of 177lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study. Clin Nucl Med. 2021;46:e523\u201330. https:\/\/doi.org\/10.1097\/rlu.0000000000003810.","journal-title":"Clin Nucl Med"},{"key":"6930_CR26","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.7150\/thno.69475","volume":"12","author":"L Zhao","year":"2022","unstructured":"Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, et al. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics. 2022;12:1557\u201369. https:\/\/doi.org\/10.7150\/thno.69475.","journal-title":"Theranostics"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06930-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06930-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06930-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T04:46:40Z","timestamp":1736830000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06930-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6930"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06930-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any experiments with animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}